| Year |
Citation |
Score |
| 2023 |
Bagel J, Gold LS, Del Rosso J, Johnson S, Yamauchi P, Brown PM, Bhatia N, Moore AY, Tallman AM. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. Journal of the American Academy of Dermatology. PMID 37172733 DOI: 10.1016/j.jaad.2023.04.061 |
0.642 |
|
| 2023 |
Zirwas MJ, Draelos ZD, DuBois J, Kircik LH, Moore AY, Stein Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green LJ, Guenthner ST, Ferris LK, Forman SB, Kempers SE, ... Yamauchi PS, et al. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial. Jama Dermatology. PMID 37133856 DOI: 10.1001/jamadermatol.2023.0846 |
0.641 |
|
| 2023 |
Nguyen W, Liu W, Yamauchi P. Drugs in Development for Chronic Spontaneous Urticaria. Journal of Drugs in Dermatology : Jdd. 22: 393-397. PMID 37026883 DOI: 10.36849/JDD.7113 |
0.592 |
|
| 2023 |
Baldwin H, Elewski B, Hougeir F, Yamauchi P, Levy-Hacham O, Hamil K, Harper J. Sixty Years of Benzoyl Peroxide Use in Dermatology. Journal of Drugs in Dermatology : Jdd. 22: 54-59. PMID 36607767 DOI: 10.36849/JDD.7150 |
0.598 |
|
| 2022 |
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, ... Yamauchi PS, et al. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. Jama. 328: 1073-1084. PMID 36125472 DOI: 10.1001/jama.2022.15632 |
0.625 |
|
| 2022 |
Naidu H, Karagaiah P, Patil A, Yamauchi P, Kircik L, Grabbe S, Goldust M. New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis. Journal of Drugs in Dermatology : Jdd. 21: 826-831. PMID 35946976 DOI: 10.36849/JDD.6443 |
0.644 |
|
| 2022 |
Ghafoor R, Patil A, Yamauchi P, Weinberg J, Kircik L, Grabbe S, Goldust M. Treatment of Scalp Psoriasis. Journal of Drugs in Dermatology : Jdd. 21: 833-837. PMID 35946971 DOI: 10.36849/JDD.6498 |
0.65 |
|
| 2022 |
Lunge SB, Shetty NS, Sardesai VR, Karagaiah P, Yamauchi PS, Weinberg JM, Kircik L, Giulini M, Goldust M. Therapeutic application of machine learning in psoriasis: A Prisma systematic review. Journal of Cosmetic Dermatology. PMID 35621249 DOI: 10.1111/jocd.15122 |
0.54 |
|
| 2022 |
Sathyan S, Agarwal K, Podder I, Patil A, Kircik L, Weinberg J, Yamauchi P, Grabbe S, Goldust M. Intralesional Mode of Drug Administration in Psoriasis. Journal of Drugs in Dermatology : Jdd. 21: 186-190. PMID 35133110 DOI: 10.36849/jdd.9169 |
0.596 |
|
| 2022 |
Kassir M, Kircik L, Weinberg J, Fatima F, Yamauchi P, Lotti T, Wollina U, Grabbe S, Goldust M. Treatment of Nail Psoriasis. Journal of Drugs in Dermatology : Jdd. 21: 146-150. PMID 35133106 DOI: 10.36849/jdd.4969 |
0.626 |
|
| 2022 |
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. The British Journal of Dermatology. PMID 34981829 DOI: 10.1111/bjd.20971 |
0.611 |
|
| 2021 |
Armstrong AW, Patil D, Levi E, McGuiness CB, Wang X, Wang Y, Chen CC, Nguyen E, Yamauchi PS. Real-World Satisfaction with Secukinumab in Clearing the Skin of Patients with Plaque Psoriasis through 24 Months of Follow-Up: Results from US Dermatology Electronic Medical Records. Dermatology and Therapy. PMID 34455554 DOI: 10.1007/s13555-021-00599-5 |
0.615 |
|
| 2021 |
Shivakumar S, Mueller SM, Yamauchi PS, Weinberg JM, Kircik L, Szepietowski JC, Goldust M. Antihistamines in Psoriasis. Journal of Drugs in Dermatology : Jdd. 20: 844-847. PMID 34397204 DOI: 10.36849/JDD.5966 |
0.588 |
|
| 2021 |
Gupta M, Weinberg JM, Yamauchi PS, Patil A, Grabbe S, Goldust M. Psoriasis: Embarking a Dynamic Shift in the Skin Microbiota. Journal of Cosmetic Dermatology. PMID 34089221 DOI: 10.1111/jocd.14273 |
0.6 |
|
| 2021 |
Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K. Bimekizumab versus Adalimumab in Plaque Psoriasis. The New England Journal of Medicine. PMID 33891379 DOI: 10.1056/NEJMoa2102388 |
0.6 |
|
| 2021 |
Zirwas M, Draelos Z, Dubois J, Kircik L, Moore A, Stein Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green L, Guenthner S, Ferris L, Forman S, Kempers S, ... Yamauchi P, et al. A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis Skin the Journal of Cutaneous Medicine. 5: s94. DOI: 10.25251/skin.5.supp.94 |
0.579 |
|
| 2021 |
Blauvelt A, Iversen L, McBride S, Gooderham M, Staubach P, Yamauchi P, Staelens F, Vanoorden V, White K, Gisondi P. Bimekizumab versus secukinumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial Skin the Journal of Cutaneous Medicine. 5: s53. DOI: 10.25251/skin.5.supp.53 |
0.615 |
|
| 2021 |
Lebwohl M, Kircik L, Moore A, Stein Gold L, Del Rosso J, Draelos Z, Gooderham M, Green L, Herbert A, Papp K, Bagel J, Bhatia N, Ferris L, Jones T, Kempers S, ... Yamauchi P, et al. Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials Skin the Journal of Cutaneous Medicine. 5: s42. DOI: 10.25251/skin.5.supp.42 |
0.614 |
|
| 2021 |
Bissonnette R, Strober B, Lebwohl M, Bagel J, Del Rosso J, Merola JF, Bhatia N, Yamauchi P, Brown PM, Rubenstein DS, Tallman AM. 25843 Tapinarof cream 1% once daily for plaque psoriasis: Patient-reported outcomes from two pivotal phase 3 trials Journal of the American Academy of Dermatology. 85: AB71. DOI: 10.1016/J.JAAD.2021.06.310 |
0.596 |
|
| 2021 |
Armstrong AW, Patil D, Levi E, McGuiness CB, Wang X, Chen C, Nguyen E, Yamauchi PS. 25561 Patient satisfaction with secukinumab on clearing the skin of psoriasis: Results from US dermatology electronic medical records Journal of the American Academy of Dermatology. 85: AB62. DOI: 10.1016/J.JAAD.2021.06.273 |
0.581 |
|
| 2020 |
Crowley JJ, Pariser DM, Yamauchi PS. A brief guide to pustular psoriasis for primary care providers. Postgraduate Medicine. 1-15. PMID 33118424 DOI: 10.1080/00325481.2020.1831315 |
0.591 |
|
| 2020 |
Gupta M, Yamauchi PS, Bagot M, Szepietowski J, Bhatia S, Lotti T, Goldust M. Uncommon presentation of morphea related to interferon beta in a patient with concomitant multiple sclerosis and chronic hepatitis C: A case report. Clinical Case Reports. 8: 1647-1650. PMID 32983469 DOI: 10.1002/ccr3.2971 |
0.574 |
|
| 2020 |
Stein Gold L, Alonso-Llamazares J, Lacour JP, Warren RB, Tyring SK, Kircik L, Yamauchi P, Lebwohl M. PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. Advances in Therapy. PMID 32965655 DOI: 10.1007/s12325-020-01497-6 |
0.643 |
|
| 2020 |
Walters ME, Lee DJ, Yamauchi PS. Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement. Journal of Drugs in Dermatology : Jdd. 19: 698-701. PMID 32845593 DOI: 10.36849/JDD.2020.5104R1 |
0.622 |
|
| 2020 |
Lebwohl M, Leonardi C, Wu JJ, Yamauchi P, Rawnsley N, Merchant M, Alexander B, Jacobson A. One-Year Pharmacovigilance Update of Brodalumab. Journal of Drugs in Dermatology : Jdd. 19: 807-808. PMID 32845586 DOI: 10.36849/JDD.2020.5138 |
0.518 |
|
| 2020 |
Patel DS, Veverka KA, Hansen JB, Yamauchi PS, Alonso-Llamazares J, Lebwohl M. Efficacy of Fixed-combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam for Scalp Plaque Psoriasis: Additional Analysis of a Phase II, Randomized Clinical Study. The Journal of Clinical and Aesthetic Dermatology. 13: 12-18. PMID 32802249 |
0.599 |
|
| 2020 |
Salimi S, Yamauchi PS, Thakur R, Weinberg JM, Kircik L, Abdelmaksoud A, Wollina U, Lotti T, Sharma A, Grabbe S, Goldust M. Interleukin 23p19 Inhibitors in Chronic Plaque Psoriasis with Focus on Mirikizumab: A Narrative Review. Dermatologic Therapy. e13800. PMID 32530083 DOI: 10.1111/dth.13800 |
0.565 |
|
| 2020 |
Gordon KB, Reich K, Crowley JJ, Korman NJ, Murphy FT, Poulin Y, Spelman L, Yamauchi PS, Mendelsohn AM, Parno J, Rozzo SJ, Ellis CN. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. The Journal of Dermatological Treatment. 1-10. PMID 32349565 DOI: 10.1080/09546634.2020.1747590 |
0.644 |
|
| 2020 |
Tyring S, Kircik LH, Yamauchi P, Jacobson A, Lin T. Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities. Journal of Drugs in Dermatology : Jdd. 19: 389-396. PMID 32272516 DOI: 10.36849/JDD.2020.4958 |
0.64 |
|
| 2020 |
Langley RG, Crowley J, Gooderham M, Papp KA, Korman NJ, Spelman L, Igarashi A, Ohtsuki M, Gupta AK, Yamauchi P, Parno J, Mendelsohn AM, Rozzo SJ, Eads K. Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2 Skin the Journal of Cutaneous Medicine. 4: s39. DOI: 10.25251/skin.4.supp.39 |
0.597 |
|
| 2020 |
Langley RG, Gooderham M, Papp KA, Yamauchi P, Thaci D, Parno J, Mendelsohn AM, Rozzo SJ, Menter A. 15910 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2 Journal of the American Academy of Dermatology. 83: AB163. DOI: 10.1016/j.jaad.2020.06.741 |
0.594 |
|
| 2020 |
Callis-Duffin K, Pinter A, Mease P, Gisondi P, Yamauchi PS, Paris M, Yang L, Levi E, Kerdel FA. 15144 Long-term safety of apremilast treatment in patients with psoriasis or psoriatic arthritis: Pooled analysis for 260 weeks and beyond in the ESTEEM 1 and 2 and PALACE 1-4 phase 3 trials Journal of the American Academy of Dermatology. 83: AB30. DOI: 10.1016/j.jaad.2020.06.207 |
0.641 |
|
| 2019 |
Green LJ, Yamauchi PS, Kircik LH. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis Journal of Drugs in Dermatology : Jdd. 18: 776-788. PMID 31424708 |
0.614 |
|
| 2019 |
Dehpouri T, Rokni GR, Narenjbon NA, Goldust M, Yamauchi PS, Wollina U, Lotti T, Kircik L, Lernia VGD, Sonthalia S, Vojvodic A, Szepietowski J, Bahadoran P, Errichetti E, Cantisani C, et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports. 11: 7965. PMID 31210916 DOI: 10.4081/dr.2019.7965 |
0.584 |
|
| 2019 |
Rathod D, Weinberg JM, Yamauchi PS, Kircik LH, Wollina U, Lotti T, Goldust M. Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report Journal of Drugs in Dermatology : Jdd. 18: 394-396. PMID 31017383 |
0.646 |
|
| 2019 |
Blauvelt A, Green LJ, Lebwohl MG, Yamauchi PS, Lin T, Martin G, Pillai R. Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis Journal of Drugs in Dermatology : Jdd. 18: 297-299. PMID 30909352 |
0.628 |
|
| 2019 |
Alexis AF, Yamauchi PS, Lin T, Martin G. Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials Skin the Journal of Cutaneous Medicine. 3: S28. DOI: 10.25251/skin.3.supp.28 |
0.633 |
|
| 2019 |
Gottlieb A, Menter A, Yamauchi P, Han G, Pillai R, Lin T, Jacobson A. Long-term Efficacy and Safety of Brodalumab in Patients With or Without History of Psoriatic Arthritis: Analysis of Two Phase 3 Psoriasis Studies Skin the Journal of Cutaneous Medicine. 3: S21. DOI: 10.25251/skin.3.supp.21 |
0.619 |
|
| 2019 |
Yamauchi P, Chen C, Ding Y, Al. E. Secukinumab Is Associated With Improvements in Real-World Effectiveness Outcomes Through 12 Months of Follow-Up in Patients With Plaque Psoriasis: Analysis of US Dermatology Electronic Medical Records Skin the Journal of Cutaneous Medicine. 3: 173. DOI: 10.25251/SKIN.3.2.13 |
0.575 |
|
| 2019 |
Yamauchi P, Chen C, Ding Y, Al. E. Demographic and Clinical Characteristics of Patients With Plaque Psoriasis Initiating Secukinumab in Clinical Practice: Data From US Dermatology Electronic Medical Records Skin the Journal of Cutaneous Medicine. 3: 172. DOI: 10.25251/SKIN.3.2.12 |
0.573 |
|
| 2019 |
Yamauchi PS, Sachsman SM, Wu JJ, Siegel M, Van Voorhees A, Armstrong A, Kay J. Biosimilars in Dermatology: Analytical, Regulatory, and Clinical Considerations: A Treatise From the Medical Board of the National Psoriasis Foundation Journal of Psoriasis and Psoriatic Arthritis. 4: 125-132. DOI: 10.1177/2475530319847660 |
0.566 |
|
| 2018 |
Sugarman JL, Weiss JS, Tanghetti EA, Soung J, Yamauchi PS, Lin T, Harris S, Martin G, Pillai R. Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies. Cutis. 102: 111-116. PMID 30893392 |
0.642 |
|
| 2018 |
Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies. Journal of Drugs in Dermatology : Jdd. 17: 855-861. PMID 30124724 |
0.64 |
|
| 2018 |
Yamauchi P, Crowley J, Kaur P, Spelman L, Warren R. Biosimilars: what the dermatologist should know. Journal of the European Academy of Dermatology and Venereology : Jeadv. PMID 29360210 DOI: 10.1111/jdv.14812 |
0.594 |
|
| 2018 |
Stein Gold L, Yamauchi P, Pariser D, Xu Z, Osterdal ML, Bagel J. Treatment with Fixed Combination Calcipotriol 50 ug/g and Betamethasone Dipropionate 0.5 mg/g Foam Provides Rapid and Significant Itch Relief in Patients with Psoriasis Skin the Journal of Cutaneous Medicine. 2: S24. DOI: 10.25251/SKIN.2.SUPP.24 |
0.598 |
|
| 2017 |
Kamel JG, Yamauchi PS. Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments. Drugs & Aging. PMID 28755089 DOI: 10.1007/s40266-017-0480-8 |
0.654 |
|
| 2016 |
Yamauchi P. DFD-01: a novel topical formulation of betamethasone dipropionate for the treatment of extensive psoriasis. Expert Review of Clinical Immunology. PMID 27967262 DOI: 10.1080/1744666X.2017.1270756 |
0.651 |
|
| 2016 |
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, ... Yamauchi PS, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology. PMID 27908543 DOI: 10.1016/j.jaad.2016.10.017 |
0.605 |
|
| 2016 |
Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Moller A, Osterdal ML, Gold LS. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study. Journal of Drugs in Dermatology : Jdd. 15: 981-987. PMID 27537999 |
0.609 |
|
| 2016 |
Matsunaga MC, Yamauchi PS. IL-4 and IL-13 Inhibition in Atopic Dermatitis. Journal of Drugs in Dermatology : Jdd. 15: 925-9. PMID 27537991 |
0.565 |
|
| 2016 |
Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, Siegel M, Wu JJ. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology. PMID 27461230 DOI: 10.1016/j.jaad.2016.06.014 |
0.609 |
|
| 2016 |
Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Olesen M, Lowson D, Yamauchi P. Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study. The Journal of Clinical and Aesthetic Dermatology. 9: 34-41. PMID 27313822 |
0.605 |
|
| 2016 |
Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. Journal of the American Academy of Dermatology. 75: 612-618.e6. PMID 27061047 DOI: 10.1016/j.jaad.2016.02.1221 |
0.625 |
|
| 2016 |
Sachsman SM, Madkan V, Yamauchi PS. Absence of Koebnerization Following Ablative and Nonablative Laser Therapy in Patients With Plaque Psoriasis. Dermatologic Surgery : Official Publication For American Society For Dermatologic Surgery [Et Al.]. 42: 521-5. PMID 26981721 DOI: 10.1097/DSS.0000000000000663 |
0.591 |
|
| 2016 |
Armstrong AW, Aldredge L, Yamauchi PS. Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners. Journal of Cutaneous Medicine and Surgery. 20: 196-206. PMID 26712930 DOI: 10.1177/1203475415623508 |
0.617 |
|
| 2015 |
Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Osterdal ML, Stein Gold L. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris - a Randomized Phase III Study (PSO-FAST). Journal of Drugs in Dermatology : Jdd. 14: 1468-77. PMID 26659941 |
0.634 |
|
| 2015 |
Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition. Journal of Drugs in Dermatology : Jdd. 14: 244-53. PMID 25738846 |
0.598 |
|
| 2015 |
Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. Jama Dermatology. 151: 432-8. PMID 25517130 DOI: 10.1001/jamadermatol.2014.3456 |
0.647 |
|
| 2015 |
Kimball AB, Rothman KJ, Kricorian G, Pariser D, Yamauchi PS, Menter A, Teller CF, Aras G, Accortt NA, Hooper M, Rice KC, Gelfand JM. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. Journal of the American Academy of Dermatology. 72: 115-22. PMID 25264239 DOI: 10.1016/J.Jaad.2014.08.050 |
0.614 |
|
| 2014 |
Yamauchi PS. Emerging permanent filler technologies: focus on Aquamid. Clinical, Cosmetic and Investigational Dermatology. 7: 261-6. PMID 25336982 DOI: 10.2147/CCID.S46650 |
0.575 |
|
| 2013 |
Kimball AB, Pariser D, Yamauchi PS, Menter A, Teller CF, Shi Y, Yong M, Creamer K, Hooper M, Aras G, Kricorian G, Gelfand JM. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis. Journal of the American Academy of Dermatology. 68: 756-64. PMID 23357569 DOI: 10.1016/J.Jaad.2012.10.055 |
0.633 |
|
| 2010 |
Yamauchi PS. Selection and preference for botulinum toxins in the management of photoaging and facial lines: patient and physician considerations. Patient Preference and Adherence. 4: 345-54. PMID 20859461 |
0.602 |
|
| 2010 |
Reinstadler A, Mau N, Bhutani T, Talkin B, Yamauchi P, Chiu M, Peng D. Perioperative use of anti-tumor necrosis factor-alfa agents. Journal of the American Academy of Dermatology. 62: 154-5. PMID 20082898 DOI: 10.1016/j.jaad.2009.04.039 |
0.551 |
|
| 2009 |
Yamauchi PS, Mau N. Adalimumab treats psoriasis in patients previously treated with etanercept: a case series. Journal of the American Academy of Dermatology. 61: 158-60. PMID 19539861 DOI: 10.1016/j.jaad.2008.12.036 |
0.603 |
|
| 2009 |
Ortiz A, Yamauchi PS. Rapidly growing squamous cell carcinoma from permanent makeup tattoo. Journal of the American Academy of Dermatology. 60: 1073-4. PMID 19467384 DOI: 10.1016/j.jaad.2008.11.902 |
0.503 |
|
| 2009 |
Yamauchi PS, Mau N. Hidradenitis suppurativa managed with adalimumab. Journal of Drugs in Dermatology : Jdd. 8: 181-3. PMID 19213236 |
0.67 |
|
| 2008 |
Gee S, Yamauchi PS. Nonsurgical management of hyperhidrosis. Thoracic Surgery Clinics. 18: 141-55. PMID 18557588 DOI: 10.1016/j.thorsurg.2008.01.003 |
0.505 |
|
| 2008 |
Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, Dann F. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. The British Journal of Dermatology. 159: 322-30. PMID 18503600 DOI: 10.1111/j.1365-2133.2008.08628.x |
0.537 |
|
| 2008 |
Yamauchi PS, Lowe NJ. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. International Journal of Dermatology. 47: 202-4. PMID 18211500 DOI: 10.1111/j.1365-4632.2008.03419.x |
0.645 |
|
| 2007 |
Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for hyperhidrosis, part 1: conservative and noninvasive treatments. Cutis. 79: 211-7. PMID 17674587 |
0.618 |
|
| 2007 |
Ram R, Lowe NJ, Yamauchi PS. Current and emerging therapeutic modalities for hyperhidrosis, part 2: moderately invasive and invasive procedures. Cutis. 79: 281-8. PMID 17500375 |
0.613 |
|
| 2006 |
Ortiz A, Yamauchi PS. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Skinmed. 5: 285-8. PMID 17085995 |
0.615 |
|
| 2006 |
Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, Kang S. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Archives of Dermatology. 142: 597-602. PMID 16702497 DOI: 10.1001/archderm.142.5.597 |
0.595 |
|
| 2006 |
Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. Journal of the American Academy of Dermatology. 54: S135-8. PMID 16488328 DOI: 10.1016/j.jaad.2005.11.1043 |
0.646 |
|
| 2006 |
Yamauchi PS, Turner L, Lowe NJ, Gindi V, Jackson JM. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. Journal of the American Academy of Dermatology. 54: S122-6. PMID 16488324 DOI: 10.1016/j.jaad.2005.11.1089 |
0.567 |
|
| 2006 |
Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. Journal of the American Academy of Dermatology. 54: S121-2. PMID 16488323 DOI: 10.1016/j.jaad.2005.10.055 |
0.58 |
|
| 2005 |
Ortiz A, Van Vliet M, Lask GP, Yamauchi PS. A review of lasers and light sources in the treatment of acne vulgaris. Journal of Cosmetic and Laser Therapy : Official Publication of the European Society For Laser Dermatology. 7: 69-75. PMID 16537211 DOI: 10.1080/14764170500206204 |
0.584 |
|
| 2005 |
van Vliet M, Ortiz A, Avram MM, Yamauchi PS. An assessment of traditional and novel therapies for cellulite. Journal of Cosmetic and Laser Therapy : Official Publication of the European Society For Laser Dermatology. 7: 7-10. PMID 16020209 DOI: 10.1080/14764170510037761 |
0.634 |
|
| 2005 |
Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 4: 138-46. PMID 15891249 |
0.629 |
|
| 2005 |
Lowe N, Yamauchi P. U.S. experience of immunomodulators in the treatment of psoriasis: reply from authors British Journal of Dermatology. 152: 818-819. DOI: 10.1111/j.1365-2133.2005.06496.x |
0.575 |
|
| 2004 |
Yamauchi PS, Lask G, Lowe NJ. Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. Journal of Cosmetic and Laser Therapy : Official Publication of the European Society For Laser Dermatology. 6: 145-8. PMID 15545098 DOI: 10.1080/14764170410023767 |
0.568 |
|
| 2004 |
Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatologic Clinics. 22: 467-76, x. PMID 15450342 DOI: 10.1016/S0733-8635(03)00126-8 |
0.633 |
|
| 2004 |
Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatologic Clinics. 22: 449-59, ix. PMID 15450340 DOI: 10.1016/j.det.2003.12.002 |
0.638 |
|
| 2004 |
Tournas JA, Lowe NJ, Yamauchi PS. Laser and novel light source treatments for psoriasis. Lasers in Surgery and Medicine. 35: 165-73. PMID 15389742 DOI: 10.1002/lsm.20083 |
0.623 |
|
| 2004 |
Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. The British Journal of Dermatology. 151: 3-15. PMID 15270867 DOI: 10.1111/j.1365-2133.2004.06009.x |
0.641 |
|
| 2004 |
Kormeili T, Yamauchi PS, Lowe NJ. Topical photodynamic therapy in clinical dermatology. The British Journal of Dermatology. 150: 1061-9. PMID 15214890 DOI: 10.1111/j.1365-2133.2004.05940.x |
0.623 |
|
| 2004 |
Lowe N, Gifford M, Tanghetti E, Poulin Y, Goldman M, Tse Y, Yamauchi P, Rosenzweig H, Kang S. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. Journal of Cosmetic and Laser Therapy : Official Publication of the European Society For Laser Dermatology. 6: 79-85. PMID 15203997 DOI: 10.1080/14764170410032406 |
0.623 |
|
| 2004 |
Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clinics in Dermatology. 22: 34-9. PMID 15158543 DOI: 10.1016/j.clindermatol.2003.11.005 |
0.587 |
|
| 2004 |
Lowe NJ, Yamauchi P. Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clinics in Dermatology. 22: 18-22. PMID 15158540 DOI: 10.1016/J.CLINDERMATOL.2003.12.025 |
0.618 |
|
| 2004 |
Strober BE, Yamauchi P, Korman N, Stevens S. Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy Journal of the American Academy of Dermatology. 50: P147. DOI: 10.1016/J.JAAD.2003.10.512 |
0.631 |
|
| 2003 |
Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ. Current systemic therapies for psoriasis: where are we now? Journal of the American Academy of Dermatology. 49: S66-77. PMID 12894129 DOI: 10.1016/mjd.2003.550 |
0.637 |
|
| 2003 |
Rohrer TE, Chatrath V, Yamauchi P, Lask G. Can patients treat themselves with a small novel light based hair removal system? Lasers in Surgery and Medicine. 33: 25-9. PMID 12866118 DOI: 10.1002/LSM.10192 |
0.595 |
|
| 2003 |
Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, Yamauchi PS. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial Journal of the American Academy of Dermatology. 48: 227-232. PMID 12582393 DOI: 10.1067/mjd.2003.49 |
0.598 |
|
| 2003 |
Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. Journal of the American Academy of Dermatology. 47: 834-40. PMID 12451366 DOI: 10.1067/MJD.2002.124070 |
0.551 |
|
| 2002 |
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery : Official Publication For American Society For Dermatologic Surgery [Et Al.]. 28: 822-7. PMID 12269876 |
0.616 |
|
| 2002 |
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Moore D. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. Journal of Cosmetic and Laser Therapy : Official Publication of the European Society For Laser Dermatology. 4: 15-8. PMID 12079632 DOI: 10.1080/14764170260030117 |
0.552 |
|
| 2002 |
Yamauchi PS, Nguyen NQ, Grimes PE. Idiopathic CD4 + T-cell lymphocytopenia associated with vitiligo Journal of the American Academy of Dermatology. 46: 779-782. PMID 12004324 DOI: 10.1067/mjd.2002.119672 |
0.53 |
|
| 2002 |
Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. The British Journal of Dermatology. 146: 118-21. PMID 11841377 DOI: 10.1046/j.0007-0963.2001.04529.x |
0.611 |
|
| 2001 |
Yamauchi PS, Soriano TT, Lask GP. Treatment of port wine stains using the pulsed-dye laser at 585 nm with the dynamic cooling device. Journal of Cutaneous Laser Therapy. 2: 33-6. PMID 11446090 DOI: 10.1080/14628830050516588 |
0.575 |
|
| 2001 |
Yamauchi PS, Kelly AP, Lask GP. Treatment of pseudofolliculitis barbae with the diode laser. Journal of Cutaneous Laser Therapy. 1: 109-11. PMID 11357287 DOI: 10.1080/14628839950516959 |
0.588 |
|
| 2000 |
Yamauchi PS, Bleharski JR, Uyemura K, Kim J, Sieling PA, Miller A, Brightbill H, Schlienger K, Rea TH, Modlin RL. A role for CD40-CD40 ligand interactions in the generation of type 1 cytokine responses in human leprosy. Journal of Immunology (Baltimore, Md. : 1950). 165: 1506-12. PMID 10903757 DOI: 10.4049/Jimmunol.165.3.1506 |
0.529 |
|
| Show low-probability matches. |